93 results about "Angiopoietin" patented technology

This invention relates to compounds, compositions, and methods useful for modulating Angiopoietin gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Angiopoietin gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Angiopoietin genes, such as Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), Angiopoietin-3 (Ang-3), and Angiopoietin-4 (Ang-4).

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF / VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.

The invention generally relates to angiogenic factors and more particularly to the angiopoietin family of growth factors and to methods of using these growth factors to induce vasodilation and hypotension and reducing hypertension.

Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.

The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding two different growth factors polypeptide components. Such a polypeptide is capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide.

Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Proheparin-binding EGF-like growth factor, Tenascin C, Angiopoietin-related protein 4, Fibroblast growth factor 19, Fibroblast growth factor 21, Heparin-binding growth factor 1, Angiopoietin-related protein 6, Proepiregulin, Probetacellulin, Amphiregulin, Angiogenin, Thrombospondin-2, and Collagen alpha-1 (XVIII) chain as diagnostic and prognostic biomarkers in renal injuries.

A method for assessing a physiological state of a mammal. The method includes: obtaining from the mammal a biological sample; measuring the expression of angiopoietin-like 2 in the biological sample; and assessing the physiological state of the mammal by comparing the measured expression of the angiopoietin-like 2 to a predetermined normal expression level in normal subjects, wherein an increase in angiopoietin-like 2 level over the predetermined normal expression level indicates an abnormal physiological state.

Compositions are described which contain lactoferrin, angiogenin and an anabolic hormone. The described compositions are useful in treatment of a variety of conditions, particularly in promoting bone health.

Methods and kits for propagating hematopoietic stem cells are provided. The methods comprise culturing cells in medium comprising one or more angiopoietin-like proteins, under conditions sufficient for expansion of HSCs. Angiopoietin-like proteins include angiopoietin-like protein 2, angiopoietin-like protein 3, angiopoietin-like protein 4, angiopoietin-like protein 5, angiopoietin-like protein 7, and microfibrillar-associated glycoprotein (Mfap4). Methods for identifying hematopoietic stem cells are provided and isolated hematopoietic stem cells are also provided.

A method for the prevention and / or treatment of a disease accompanied by vascular leakage and / or vascular inflammation comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.

The invention discloses a freeze-dried gel cosmetic and preparation method and application thereof. The freeze-dried gel cosmetic of the invention comprises the following components by weight percent: 0.5-3% of chitosan, 1-10% of stabilizing agent, 0.0001-0.001% of coenzyme Q10, 0.00001-0.001% of metallothionein, 0.00001-0.001% of recombinant human angiopoietin-1 and 0.01-0.2% of low molecular weight heparin sodium, the balance of water. The freeze-dried gel cosmetic of the invention can be used for daily skin care and has the beauty effects of whitening, postponing senility and enhancing skin elasticity.

An antiobesity drug, a remedy for diabetes and / or a remedy for hyperlipemia containing angiopoietin-related growth factor (AGF) or a polynucleotide encoding the same as the active ingredient; a functional food or a health food containing AGF as the active ingredient and having a function of ameliorating obesity, diabetes and / or hyperlipemia imparted thereto; a method of preventing or treating obesity, diabetes and / or hyperlipemia which comprises administering AGF or a polynucleotide encoding the same; and utilization of AGF or a polynucleotide encoding the same for producing an antiobesity drug, a remedy for diabetes and / or a remedy for hyperlipemia.

The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

The invention provides a preparation method of a human stem cell with prolonged service life and enhanced angiogenesis. The preparation method comprises the following steps of establishing gene segments of a RNA (ribonucleic acid) testis signal transduction and activating body and angiogenin-1; and recombining the gene segments to a virus expression vector. The service life of the cell can be prolonged by transfection of the human stem cell, the angiogenesis of the human stem cell is improved, and tumorigenesis is avoided. The invention also provides a kit of the human stem cell with the prolonged service life and the enhanced angiogenesis, and the human stem cell is expected to treat ischemic cardiovascular and cerebrovascular diseases well.

The invention provides compositions and methods for protecting vascular tissues from injury that occurs, for example, during occlusion of one or more arteries. In some embodiments, the injury is myocardial infarction. The compositions of the invention include combinations of platelet derived growth factor, vascular endothelial growth factor, and angiopoietin-2.

A pharmaceutical composition for therapy of coronary artery narrowing or blockage, which comprises a sustained release preparation containing an angiogenesis factor or a gene encoding the same and a gelatin hydrogel is disclosed. Examples of the angiogenesis factor which may be used include e.g., bFGF and other FGFs, VEGF, HGF, PDGF, TGF, angiopoietin, HIF, cytokine, chemokine, adrenomeduline and the like.

The present invention provides methods for treating ischemic diseases, which comprise the step of administering angiopoietin-1 (Ang1) or an Ang1-encoding vector. The present invention also provides ischemic disease treatment kits which comprise Ang1. Ang1-expressing vectors were prepared, and each was administered alone intramyocardially to rats in the acute phase of myocardial infarction to express Ang1 in the local cardiac muscle. The results indicate that marked effects have been obtained, such as decrease in post-infarction mortality rate, increase in blood vessel number in myocardium, reduction of myocardial infarct size, and improvement of cardiac function. Administration of the required VEGF was not necessary for the angiogenic activity of Ang1. Furthermore, when an Ang1viral expression vector was administered alone to an animal model of severe limb ischemia, in which ischemia had been induced by arterial ligation, a remarkable limb salvage effect was obtained. The Ang1 gene therapy is excellent as a safe and effective therapeutic method for ischemic diseases such as ischemic heart diseases and limb ischemia.

The invention discloses an anti-ANGPTL3 (angiopoietin-like protein) monoclonal antibody. The heavy chain amino acid sequence of the monoclonal antibody is SEQ ID: No 1, the light chain amino acid sequence of the monoclonal antibody is SEQ ID: No 2, the heavy chain DNA (deoxyribonucleic acid) sequence of the monoclonal antibody is SEQ ID: No 3, and the light chain DNA sequence of the monoclonal antibody is SEQ ID: No 4. The invention also discloses application of the anti-ANGPTL3 monoclonal antibody in preparing a medicine capable of treating a nephrotic syndrome. The anti-ANGPTL3 monoclonal antibody specifically identifies an ANGPTL3, blocks a fibrinogen-like structural domain of the ANGPTL3, and antagonizes the injury of the ANGPTL3 to sertoli cells. The invention can be used for detecting the ANGPTL3 and is hopefully used for treating nephrotic syndrome proteinuria.

The invention relates to a cheese includes angiogenin and / or angiogenin hydrolysate in an amount of 6.5 mg / 100 g to 160 mg / 100 g, and lactoperoxidase and / or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and / or angiogenin hydrolysate of 0.3 to 33.

Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin [alpha]5[beta]1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin [alpha]5[beta]1-mediated Rac1 / PAK signaling to weaken cell-cell contacts. Subsequently, cANGPTL4 is associated with and declusters VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption. In vivo vascular permeability and metastatic assays performed using ANGPTL4-knockout and wild-type mice injected with either control or ANGPTL4-knockdown tumors confirmed that cANGPTL4 induced vascular leakiness and facilitated lung metastasis in mice. Therefore, our findings elucidate how cANGPTL4 induces endothelial disruption. Our findings have direct implications for targeting cANGPTL4 to treat cancer and other vascular pathologies.

A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.

The invention relates to sulfonamido-macrocycles according to the general Formula I and the salts thereof, to pharmaceutical compositions comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling, wherein R<1>, R<2> and R<3> have the meaning as given in the specification and the claims.